<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">22409</article-id><article-id pub-id-type="doi">10.7554/eLife.22409</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Lovastatin fails to improve motor performance and survival in <italic>methyl-CpG-binding protein2</italic>-null mice</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-71886"><name><surname>Villani</surname><given-names>Claudia</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6334-9013</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-71986"><name><surname>Sacchetti</surname><given-names>Giuseppina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-71888"><name><surname>Bagnati</surname><given-names>Renzo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-71889"><name><surname>Passoni</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-71890"><name><surname>Fusco</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-71891"><name><surname>Carli</surname><given-names>Mirjana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-71334"><name><surname>Invernizzi</surname><given-names>Roberto William</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6017-9781</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Laboratory of Neurochemistry and Behaviour, Department of Neuroscience</institution>, <institution>Istituto di Ricerche Farmacologiche Mario Negri</institution>, <addr-line><named-content content-type="city">Milano</named-content></addr-line>, <country>Italy</country></aff><aff id="aff2"><institution content-type="dept">Analytical Instrumentation Unit, Department of Environmental Health Sciences</institution>, <institution>Istituto di Ricerche Farmacologiche Mario Negri</institution>, <addr-line><named-content content-type="city">Milano</named-content></addr-line>, <country>Italy</country></aff><aff id="aff3"><institution content-type="dept">Genetics of Neurodegenerative Diseases Unit, Department of Neuroscience</institution>, <institution>Istituto di Ricerche Farmacologiche Mario Negri</institution>, <addr-line><named-content content-type="city">Milano</named-content></addr-line>, <country>Italy</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-12058"><name><surname>Monteggia</surname><given-names>Lisa</given-names></name><role>Reviewing editor</role><aff><institution>University of Texas Southwestern Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>rinvernizzi@marionegri.it</email> (RI);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>11</month><year>2016</year></pub-date><volume>5</volume><elocation-id>e22409</elocation-id><history><date date-type="received"><day>15</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>Â© 2016, Villani et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Villani et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-22409-v1.pdf"/><abstract><p>Previous studies provided evidence for the alteration of brain cholesterol homeostasis in 129<italic>.Mecp2</italic>-null mice, an experimental model of Rett syndrome. The efficacy of statins in improving motor symptoms and prolonging survival of mutant mice suggested a potential role of statins in the therapy of Rett syndrome. In the present study, we show that <italic>Mecp2</italic> deletion had no effect on brain and serum cholesterol levels and lovastatin (1.5 mg/kg, twice weekly as in the previous study) had no effects on motor deficits and survival when <italic>Mecp2</italic> deletion was expressed on a background strain (C57BL/6J; B6) differing from that used in the earlier study. These findings indicate that the effects of statins may be background specific and raise important issues to consider when contemplating clinical trials. The reduction of the brain cholesterol metabolite 24S-hydroxycholesterol found in B6.<italic>Mecp2</italic>-null mice suggests the occurrence of changes in brain cholesterol metabolism and the potential utility of using plasma levels of 24S-OHC as a biomarker of brain cholesterol homeostasis in RTT.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Istituto di Ricerche Farmacologiche Mario Negri</institution></institution-wrap></funding-source><award-id>Intramural funding</award-id><principal-award-recipient><name><surname>Invernizzi</surname><given-names>Roberto William</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The Istituto di Ricerche Farmacologiche &quot;Mario Negri&quot; adheres to the principle set out in the following law, regulations, and policies governing the care and use of laboratory animals: Italian Governing Law (D.lgs.26/2014; Authorisation n. 19/2008-A issued March 6, 2008 by Ministry of Health); Mario Negri Institutional Regulations and Policies providing internal authorization for persons conducting animal experiments (Quality Management System Certificate - UNI EN ISO 9001:2008 - Reg. N{degree sign} 6121); the NIH Guide for the Care and Use of Laboratory Animals (2011 edition) and EU directives and guidelines (EEC Council Directive 2010/63/UE). The statement of Compliance (Assurance) with the Public Health Service (PHS) Policy on Human Care and Use of Laboratory Animals has been recently reviewed (9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance #A5023-01). The protocol was approved by the Italian Ministry of Health (Permit Number 946/2015-PR).</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-22409-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>